ArrePath, Princeton, New Jersey, USA
https://arrepath.com/

ArrePath is executing a Lead Optimization workplan for its first-in-class antibiotic targeting a clinically novel target for the treatment of complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales. Using its proprietary, artificial intelligence and machine-learning-enabled platform, ArrePath has identified a series of inhibitors with a novel mechanism of action against a highly conserved target but clinically-unexploited in Gram-negative bacteria with no human homolog.

If successfully developed, ArrePath’s novel antibiotic class will be active against the vast majority of MDR Enterobacterales infections, representing an important new tool in the fight against antimicrobial resistance. ArrePath’s inhibitors have attributes that suggest they can be administered orally as well as by IV. This combination is imperative for treating MDR infections in the community and outpatient settings, allowing hospitalized patients being treated with an IV to switch to oral therapy when appropriate.

Current Development Stage: Lead Optimization

CARB-X Investment: Initial investment of US$3.7M

Initial CARB-X Investment Date: April 2, 2025